Cargando…

Multiplexed VaxArray immunoassay for rapid antigen quantification in measles and rubella vaccine manufacturing

Measles-containing vaccines (MCV), specifically vaccines against measles and rubella (MR), are extremely effective and critical for the eradication of measles and rubella diseases. In developed countries, vaccination rates are high and vaccines are readily available, but continued high prevalence of...

Descripción completa

Detalles Bibliográficos
Autores principales: Gillis, Jacob H., Thomas, Keely N., Manoharan, Senthilkumar, Panchakshari, Mallikarjuna, Taylor, Amber W., Miller, David F., Byrne-Nash, Rose T., Riley, Christine, Rowlen, Kathy L., Dawson, Erica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8484809/
https://www.ncbi.nlm.nih.gov/pubmed/34622199
http://dx.doi.org/10.1016/j.jvacx.2021.100113
_version_ 1784577399339352064
author Gillis, Jacob H.
Thomas, Keely N.
Manoharan, Senthilkumar
Panchakshari, Mallikarjuna
Taylor, Amber W.
Miller, David F.
Byrne-Nash, Rose T.
Riley, Christine
Rowlen, Kathy L.
Dawson, Erica
author_facet Gillis, Jacob H.
Thomas, Keely N.
Manoharan, Senthilkumar
Panchakshari, Mallikarjuna
Taylor, Amber W.
Miller, David F.
Byrne-Nash, Rose T.
Riley, Christine
Rowlen, Kathy L.
Dawson, Erica
author_sort Gillis, Jacob H.
collection PubMed
description Measles-containing vaccines (MCV), specifically vaccines against measles and rubella (MR), are extremely effective and critical for the eradication of measles and rubella diseases. In developed countries, vaccination rates are high and vaccines are readily available, but continued high prevalence of both diseases in developing countries and surges in measles deaths in recent years have highlighted the need to expand vaccination efforts. To meet demand for additional vaccines at a globally affordable price, it is highly desirable to streamline vaccine production thereby reducing cost and speeding up time to delivery. MR vaccine characterization currently relies on the 50% cell culture infectious dose (CCID(50)) assay, an endpoint assay with low reproducibility that requires 10–14 days to complete. For streamlining bioprocess analysis and improving measurement precision relative to CCID(50), we developed the VaxArray Measles and Rubella assay kit, which is based on a multiplexed microarray immunoassay with a 5-hour time to result. Here we demonstrate vaccine-relevant sensitivity ranging from 345 to 800 IFU/mL up to 100,000 IFU/mL (infectious units per mL) and specificity that allows simultaneous analysis in bivalent vaccine samples. The assay is sensitive to antigen stability and has minimal interference from common vaccine additives. The assay exhibits high reproducibility and repeatability, with 15% CV, much lower than the typical 0.3 log(10) error (∼65%) observed for the CCID(50) assay. The intact protein concentration measured by VaxArray is reasonably correlated to, but not equivalent to, CCID(50) infectivity measurements for harvest samples. However, the measured protein concentration exhibits equivalency to CCID(50) for more purified samples, including concentrated virus pools and monovalent bulks, making the assay a useful new tool for same-day analysis of vaccine samples for bioprocess development, optimization, and monitoring.
format Online
Article
Text
id pubmed-8484809
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-84848092021-10-06 Multiplexed VaxArray immunoassay for rapid antigen quantification in measles and rubella vaccine manufacturing Gillis, Jacob H. Thomas, Keely N. Manoharan, Senthilkumar Panchakshari, Mallikarjuna Taylor, Amber W. Miller, David F. Byrne-Nash, Rose T. Riley, Christine Rowlen, Kathy L. Dawson, Erica Vaccine X Regular paper Measles-containing vaccines (MCV), specifically vaccines against measles and rubella (MR), are extremely effective and critical for the eradication of measles and rubella diseases. In developed countries, vaccination rates are high and vaccines are readily available, but continued high prevalence of both diseases in developing countries and surges in measles deaths in recent years have highlighted the need to expand vaccination efforts. To meet demand for additional vaccines at a globally affordable price, it is highly desirable to streamline vaccine production thereby reducing cost and speeding up time to delivery. MR vaccine characterization currently relies on the 50% cell culture infectious dose (CCID(50)) assay, an endpoint assay with low reproducibility that requires 10–14 days to complete. For streamlining bioprocess analysis and improving measurement precision relative to CCID(50), we developed the VaxArray Measles and Rubella assay kit, which is based on a multiplexed microarray immunoassay with a 5-hour time to result. Here we demonstrate vaccine-relevant sensitivity ranging from 345 to 800 IFU/mL up to 100,000 IFU/mL (infectious units per mL) and specificity that allows simultaneous analysis in bivalent vaccine samples. The assay is sensitive to antigen stability and has minimal interference from common vaccine additives. The assay exhibits high reproducibility and repeatability, with 15% CV, much lower than the typical 0.3 log(10) error (∼65%) observed for the CCID(50) assay. The intact protein concentration measured by VaxArray is reasonably correlated to, but not equivalent to, CCID(50) infectivity measurements for harvest samples. However, the measured protein concentration exhibits equivalency to CCID(50) for more purified samples, including concentrated virus pools and monovalent bulks, making the assay a useful new tool for same-day analysis of vaccine samples for bioprocess development, optimization, and monitoring. Elsevier 2021-09-20 /pmc/articles/PMC8484809/ /pubmed/34622199 http://dx.doi.org/10.1016/j.jvacx.2021.100113 Text en © 2021 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Regular paper
Gillis, Jacob H.
Thomas, Keely N.
Manoharan, Senthilkumar
Panchakshari, Mallikarjuna
Taylor, Amber W.
Miller, David F.
Byrne-Nash, Rose T.
Riley, Christine
Rowlen, Kathy L.
Dawson, Erica
Multiplexed VaxArray immunoassay for rapid antigen quantification in measles and rubella vaccine manufacturing
title Multiplexed VaxArray immunoassay for rapid antigen quantification in measles and rubella vaccine manufacturing
title_full Multiplexed VaxArray immunoassay for rapid antigen quantification in measles and rubella vaccine manufacturing
title_fullStr Multiplexed VaxArray immunoassay for rapid antigen quantification in measles and rubella vaccine manufacturing
title_full_unstemmed Multiplexed VaxArray immunoassay for rapid antigen quantification in measles and rubella vaccine manufacturing
title_short Multiplexed VaxArray immunoassay for rapid antigen quantification in measles and rubella vaccine manufacturing
title_sort multiplexed vaxarray immunoassay for rapid antigen quantification in measles and rubella vaccine manufacturing
topic Regular paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8484809/
https://www.ncbi.nlm.nih.gov/pubmed/34622199
http://dx.doi.org/10.1016/j.jvacx.2021.100113
work_keys_str_mv AT gillisjacobh multiplexedvaxarrayimmunoassayforrapidantigenquantificationinmeaslesandrubellavaccinemanufacturing
AT thomaskeelyn multiplexedvaxarrayimmunoassayforrapidantigenquantificationinmeaslesandrubellavaccinemanufacturing
AT manoharansenthilkumar multiplexedvaxarrayimmunoassayforrapidantigenquantificationinmeaslesandrubellavaccinemanufacturing
AT panchaksharimallikarjuna multiplexedvaxarrayimmunoassayforrapidantigenquantificationinmeaslesandrubellavaccinemanufacturing
AT tayloramberw multiplexedvaxarrayimmunoassayforrapidantigenquantificationinmeaslesandrubellavaccinemanufacturing
AT millerdavidf multiplexedvaxarrayimmunoassayforrapidantigenquantificationinmeaslesandrubellavaccinemanufacturing
AT byrnenashroset multiplexedvaxarrayimmunoassayforrapidantigenquantificationinmeaslesandrubellavaccinemanufacturing
AT rileychristine multiplexedvaxarrayimmunoassayforrapidantigenquantificationinmeaslesandrubellavaccinemanufacturing
AT rowlenkathyl multiplexedvaxarrayimmunoassayforrapidantigenquantificationinmeaslesandrubellavaccinemanufacturing
AT dawsonerica multiplexedvaxarrayimmunoassayforrapidantigenquantificationinmeaslesandrubellavaccinemanufacturing